Thrivent Financial for Lutherans Lowers Holdings in Johnson & Johnson $JNJ

Key Points

• Thrivent Financial for Lutherans reduced its Johnson & Johnson stake by 11.6% in the fourth quarter, selling 204,930 shares and leaving it with 1,568,944 shares valued at about $324.7 million.
• Johnson & Johnson reported solid quarterly results, posting $2.70 EPS and $24.06 billion in revenue, both above expectations, while revenue rose 9.9% year over year.
• The company boosted its dividend to $1.34 per share quarterly from $1.30, implying an annualized payout of $5.36 and a yield of about 2.3%.

Thrivent Financial for Lutherans cut its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 11.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,568,944 shares of the company's stock after selling 204,930 shares during the period. Johnson & Johnson accounts for 0.6% of Thrivent Financial for Lutherans' holdings, making the stock its 19th biggest holding. Thrivent Financial for Lutherans owned 0.07% of Johnson & Johnson worth $324,691,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in the business. Plancorp LLC lifted its holdings in Johnson & Johnson by 0.3% in the 4th quarter. Plancorp LLC now owns 15,889 shares of the company's stock worth $3,288,000 after purchasing an additional 45 shares in the last quarter. WealthCollab LLC lifted its holdings in Johnson & Johnson by 4.7% in the 4th quarter. WealthCollab LLC now owns 1,015 shares of the company's stock worth $210,000 after purchasing an additional 46 shares in the last quarter. MMA Asset Management LLC lifted its holdings in Johnson & Johnson by 1.3% in the 4th quarter. MMA Asset Management LLC now owns 3,600 shares of the company's stock worth $745,000 after purchasing an additional 46 shares in the last quarter. Vista Investment Partners II LLC lifted its holdings in Johnson & Johnson by 1.2% in the 4th quarter. Vista Investment Partners II LLC now owns 3,811 shares of the company's stock worth $789,000 after purchasing an additional 47 shares in the last quarter. Finally, Campbell Deegan Wealth Management LLC lifted its holdings in Johnson & Johnson by 1.6% in the 4th quarter. Campbell Deegan Wealth Management LLC now owns 2,990 shares of the company's stock worth $619,000 after purchasing an additional 48 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $230.61 on Friday. The stock's fifty day moving average is $235.49 and its 200 day moving average is $221.76. Johnson & Johnson has a fifty-two week low of $147.33 and a fifty-two week high of $251.71. The firm has a market capitalization of $555.13 billion, a PE ratio of 26.66, a PEG ratio of 2.26 and a beta of 0.27. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.77 and a current ratio of 1.03.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.02. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The company had revenue of $24.06 billion for the quarter, compared to analyst estimates of $23.60 billion. During the same quarter in the prior year, the firm posted $2.77 EPS. Johnson & Johnson's quarterly revenue was up 9.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. On average, sell-side analysts anticipate that Johnson & Johnson will post 11.57 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th will be paid a $1.34 dividend. The ex-dividend date is Tuesday, May 26th. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.30. This represents a $5.36 dividend on an annualized basis and a yield of 2.3%. Johnson & Johnson's payout ratio is 60.12%.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Leerink Partners upgraded Johnson & Johnson to Outperform and lifted its price target, citing stronger growth prospects from upcoming drug launches and broader oncology/immunology momentum. Article Title
• Positive Sentiment: New clinical and commercial updates around CAPLYTA, cardiology, Crohn’s disease, and robotics may support confidence in J&J’s innovation pipeline. Article Title
• Neutral Sentiment: J&J’s stock remains below some recent highs and has been consolidating after earnings, suggesting investors are still weighing valuation and execution. Article Title
• Negative Sentiment: A bladder-cancer survey highlighted the significant burden of current standard treatments, which may reinforce concerns about unmet needs and the pace of innovation in that area. Article Title

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Timothy Schmid sold 1,322 shares of the stock in a transaction on Friday, February 20th. The stock was sold at an average price of $245.66, for a total value of $324,762.52. Following the sale, the executive vice president owned 25,447 shares in the company, valued at $6,251,310.02. This trade represents a 4.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Vanessa Broadhurst sold 6,197 shares of the stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total value of $1,508,287.83. Following the completion of the sale, the executive vice president owned 23,003 shares in the company, valued at approximately $5,598,700.17. The trade was a 21.22% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 30,142 shares of company stock worth $7,360,528. Insiders own 0.16% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on JNJ shares. Wall Street Zen cut Johnson & Johnson from a "buy" rating to a "hold" rating in a report on Saturday, February 14th. Freedom Capital cut Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a report on Friday, January 16th. Loop Capital set a $220.00 price objective on Johnson & Johnson in a report on Tuesday, January 27th. Barclays upped their price objective on Johnson & Johnson from $234.00 to $255.00 and gave the stock an "equal weight" rating in a report on Wednesday, April 15th. Finally, Rothschild & Co Redburn upped their price objective on Johnson & Johnson from $180.00 to $210.00 and gave the stock a "neutral" rating in a report on Thursday, February 19th. Twenty analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $253.04.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.